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Before the era of molecular biology, the methods available for an understanding of gene 
function were limited. Such studies typically relied on the ability to identify and isolate 
naturally occurring variants exhibiting a defect in function. Hence, the progress was slow in 
this regard. The discoveries in the field of microbiology, combined with advances in 
technology in the later part of 20th century, dramatically changed this scenario. The current 
molecular biological techniques enable site-directed mutagenesis approaches for generating 
a gene with a specific amino acid substitution, mutation, or a deletion or for truncating a 
gene anywhere in a matter of days. 
The present review highlights the studies conducted on human immunodeficiency virus 
type 1 (HIV-1) Vpr, an auxiliary protein associated with virus particles. Vpr contains 96 
amino acids, and it is a multifunctional protein. To analyze the contribution of specific 
residues to protein function and to the cytopathic effects in HIV-1-infected individuals, 
investigators from several laboratories, including ours, took advantage of a novel approach. 
Specifically, this approach involved exchange of residues through mutagenesis. The choice 
of residue was based on the information available regarding the naturally occurring 
polymorphisms at the level of individual amino acids in Vpr. The results from these studies 
support a link between polymorphisms in these genes and the disease status of infected 
individuals, who are known as progressors or non-progressors. In addition the studies have 
shed light on the structure-function relationship of Vpr.  
The Joint United Nations Program on HIV/AIDS (UNAIDS) (2010) reports that the 
worldwide prevalence of those living with human immunodeficiency virus (HIV) is 
between 31-35 million as of the end of 2009. Roughly 2.6 million new cases of HIV infection 
occurred in the same year. That number has likely remained approximately constant. 
                                                 
* Corresponding Author 
 
Genetic Manipulation of DNA and Protein – Examples from Current Research 
 
204 
Although the most common route of HIV infection is via sexual contact, the use of 
contaminated drug paraphernalia, mother-child transmission via pregnancy or 
breastfeeding, and tainted blood transfusions comprise other means of infection.  
The symptomatic outcome of infection is AIDS, usually occurring ~10 years after initial 
infection. CD4+ T-cell counts drop below 200, and subsequent severe immune dysfunction 
results. This eventually leads to fatal coinfection by opportunistic pathogens. The advent of 
highly active retroviral therapy (HAART) in the 1990s led to a drastically improved 
prognosis for AIDS patients (Peters and Conway, 2011). This triple-drug cocktail controls 
viremia and allows immune function to recover to nearly uninfected levels, with the caveat 
of near-perfect patient adherence to a difficult combination of drug regimens. The extremely 
rigid treatment schedules have resulted in low compliance, leading to the emergence of 
viruses that exhibit resistance to drugs.  
2. Genetic organization of HIV 
The causative agents of AIDS have been identified as human immunodeficiency virus types 
1 (HIV-1) and 2 (HIV-2). Both HIV-1 and HIV-2 are members of the lentivirus family of 
retroviruses. HIV-1 is the predominant virus responsible for AIDS throughout the world. 
The schematic representation of the genome organization of HIV-1 is shown in Figure 1. The 
genome of HIV-1 codes for two regulatory proteins (Tat and Rev) and four auxiliary 
proteins (Vif, Vpr Vpu and Nef), in addition to structural proteins Gag, Gag-Pol and Env. 
The genome organization of HIV-2 is similar to HIV-1. The unique genes are vpu and vpx for 
HIV-1 and HIV-2, respectively. With respect to viral morphogenetic events, the lentiviruses 
are similar to alpharetroviruses, gammaretroviruses and deltaretroviruses. During virus 
infection, Gag and Gag-Pol proteins are synthesized in the cytoplasm and transported to the 
cell membrane, where virus assembly occurs. In the case of HIV-1, the non-structural 
proteins Vpr, Vif, and Nef are also packaged into the virus particles. 
 
Fig. 1. Organization of the HIV-1 Genome. 
3. Heterogeneity in the human immunodeficiency virus  
Within HIV-1-positive patients, the high error rate of reverse transcription can produce 
many variants, or quasispecies. After seroconversion to HIV-positive status, the viral loads 
measure at 10000-50000 viral RNA copies per ml of patient sera during the asymptomatic 
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stage; in the later stages of disease, viral RNA genomes can increase to several million copies 
per ml (Poropatich and Sullivan, 2011; Tungaturthi et al., 2004). Thus, a high replication rate 
produces tremendous variation in the viral population within a single patient. The pressures 
of the host immune response drive the selection of variants from early stages of infection, 
until the host immune response cannot cope with the viral diversity (Fischer et al., 2010; 
Wolinsky et al., 1996). 
Studies of polymorphisms in a number of the genes of HIV-1 confirm the propensity of the 
virus to escape host immunity (Fischer et al., 2010; Fischer et al., 2007; Gaschen et al., 2002; 
Korber et al., 2001). As expected, the antigenic Env protein exhibits the highest mutability. 
Comparisons of current strains of HIV show a staggering 20% variability within a subtype 
and up to 35% variability between subtypes (Gaschen et al., 2002). To highlight the problem 
of this variability in vaccine development, the evolutionary dynamics of influenza virus 
provides a revealing picture. The influenza genome varies by 1-2% per year, enabling 
influenza virus escape from polyclonal vaccine responses and necessitating annual vaccine 
changes (Fischer et al., 2007; Gaschen et al., 2002). Along with intra- and inter-subtype 
variation in HIV, env shows on average a 10% change in genetic diversity over the course of 
an infection in a single patient (Korber et al., 2001). In addition to the env gene, Korber et al. 
(2001) estimated the percent variation in sequences culled from an HIV-1 database 
compared to the HXB2 strain consensus in tat and gag. They found 9% and 5% variation, 
respectively. From another study, gag and pol remained relatively conserved; but the rest of 
the genes exhibited high variability comparable to that of env (Gaschen et al., 2002) (Figure 
1). The vast genetic diversity seen in these studies thus far exemplifies the major obstacle to 
vaccine development. 
The variation in the viral genome throughout the population potentially correlates with the 
variation among HIV-infected individuals. In the progressor group, in which AIDS develops 
10 years after initial infection, CD4+ T-cell counts (the primary marker of AIDS progression) 
generally fall below 200 cells per μl and causing loss of cell-mediated immunity (Levy, 
2009). Along with the normal progressors, several other categories of disease progression 
exist. Long term non-progressors (LTNPs) and elite controllers (EC) do not receive HAART 
and do not show the aforementioned clinical signs of AIDS for up to 20 years after infection. 
CD4+ T-cell counts are maintained to levels above 350 cells per μl and viral loads to under 
2000 copies per ml. Viral loads in these groups can range as low as 50-2000 copies per ml 
(Poropatich and Sullivan, 2011). In rapid progressors (RP), CD4+ T-cell counts generally 
decline 3-8 years postinfection. Although individual host genetics likely play a role in 
differential disease progression (Goulder et al., 1997), the presence of multiple quasispecies 
in patients potentially explains the differences in disease outcome. 
4. Polymorphisms in specific HIV-1 genes 
Several genes of HIV have a functional role in disease symptoms (Caly et al., 2008; Casartelli 
et al., 2003; Tolstrup et al., 2006). As Nef downregulates MHC class I antigen presentation 
involved in generating a cytotoxic T-lymphocyte (CTL) response, polymorphisms in this 
gene correlate with the LTNP group (Caly et al., 2008; Casartelli et al., 2003; Tolstrup et al., 
2006). Similarly the role of Tat as a transactivator of the HIV-1 promoter in the long-
terminal-repeat (LTR) region and its genetic heterogeneity suggest a functional role for Tat 
in disease progression and outcome (Bratanich et al., 1998; Korber et al., 2001). Tat can 
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upregulate LTR-transcriptional activity and thus replication. Cellular and viral transcription 
increases several hundredfold (Irish et al., 2009) in the presence of Tat. Various Tat proteins 
isolated from different subtypes show differences in the ability to induce viral and cellular 
gene transcription (Roof et al., 2002). 
The multifunctional Viral Protein R (Vpr), although labeled as an accessory protein, has a 
vital role in efficient replication of the virus in the non-dividing macrophages and 
monocytes (Balliet et al., 1994; Connor et al., 1995). Vpr interacts with the Gag protein for 
packaging into the virion. It remains bound to the preintegration complex (PIC) upon entry 
of the viral contents into the target cell during infection, most likely aiding PIC entry into 
the nucleus. It has a highly functional role in replication as a transactivator of the LTR, 
binding to a number of host transcription factors, such as Sp1 (Sawaya et al., 1998) and TFIIB 
(Agostini et al., 1999). Extensive studies have shown that coactivation of glucocorticoid 
receptor by Vpr, resulting in transcription of elements in the promoter regions of the HIV 
LTR and host genes, enhances viral replication and downregulates host immune responses 
(Ayyavoo et al., 1997; Hapgood and Tomasicchio, 2010). Vpr also drives apoptosis and G2 
cell cycle arrest (Morellet et al., 2009; Pandey et al., 2009; Tungaturthi et al., 2004). The 
processes enhance immune escape and HIV-1 replication, respectively. As Vpr seems to be 
essential in the viral life cycle, it is likely that vpr gene sequences will exhibit signature 
changes among the categories of HIV-1 disease progression. Due to the importance of Vpr, 
this review focuses mainly on the polymorphisms in vpr, their effects on Vpr function, and 
their potential consequences on disease outcome. The review will also show how using an in 
vitro model to study polymorphisms may help us better understand the mechanisms and 
develop therapeutics for treatment. 
5. Methods used to generate mutations to study gene regulation  
Identifying genes responsible for different phenotypes previously relied on isolating 
naturally occurring polymorphic genes within the organisms. This process is time-
consuming and requires sequencing several isolates to identify the functionally relevant 
genes. Today there are many different means of following the general path of altering the 
genotype to observe the phenotype. 
5.1 Site-directed mutagenesis 
The use of a point mutation to observe the change of function that occurs as a result of a 
change in structure underscores the majority of studies on the role of polymorphisms in 
viral and host gene function. One method of generating a targeted mutation in a plasmid 
construct carrying the gene of interest uses a polymerase chain reaction (PCR) technique. 
This particular PCR-based method has the advantage of using a high-fidelity polymerase 
and methylation of DNA by common strains of Escherichia coli. The protocol is described as 
part of the commercially available QuikChange IITM Site-Directed Mutagenesis Kit (Agilent, 
2010). PCR results in the amplification of daughter DNA strands that carry the mutation of 
interest (Agilent, 2010). In the initial PCR amplification step, two primers containing the 
mutation of interest bind to the complementary strands of the plasmid. This requires a 
mismatch of at least one nucleotide on the primers and, furthermore, optimization of the 
length of the primer for a suitable Tm for the annealing step of the PCR. The mismatch limits 
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the number of mutations that can be made per reaction to about four bases, depending on 
the length and Tm of the primer. 
PCR will copy the entire parental template. The high-fidelity Pfu Ultra polymerase has an 
error rate of one per 2.5×106 nucleotides (Agilent, 2011), making the errors introduced by 
PCR a non-issue. Once the amplification of the template is complete, the PCR product 
contains the original parental DNA strands and the mutated and amplified daughter DNA 
strands. To select against the parental strands, the protocol takes advantage of the fact that 
the mutated and amplified daughter strands are unmethylated. In contrast, the parental 
(template) strands are methylated, as they originated from methylation-capable E. coli. 
Digesting the PCR product with DpnI endonuclease, which digests methylated and hemi-
methylated DNA, will cleave the parental strands and leave the daughter strands intact. 
Since the amplified DNA has the plasmid sequence of the parent and since there is an 
overlap region to allow circularization by homologous recombination, plasmids with the 
mutation are then isolated by transformation. Any candidate must then be screened and 
sequenced to confirm the mutagenesis. 
6. Structure and function relationship of HIV-1 Vpr 
To arrive at the structure of Vpr, several NMR studies have used fragments representing 
different segments of the Vpr protein. Alternatively the entire Vpr molecule has been 
analyzed in an appropriate solvent (Morellet et al., 2003; Wecker et al., 2002). The analyses 
showed a flexible N-terminus with a turn, the first alpha helix, turn, the second alpha helix, 
turn, the third alpha helix, then a flexible C-terminal domain (Morellet et al., 2003; Wecker et 
al., 2002). Morellet et al. (2003) used a different solvent, allowing them to “see” the tertiary 
structure of Vpr. The solvent was better at revealing the hydrophobic parts that are 
implicated in dimerization and interaction with other proteins (Morellet et al., 2003). Ideally 
NMR studies of protein structure employ solvents and conditions that approximate 
physiological conditions. However, the oligomerization property of Vpr makes proper 
solvation extremely difficult. Several studies have used trifluoroethanol (TFE), a 
hydrophobic solvent, in different proportions to counteract the interaction of the 
hydrophobic domains of Vpr, some of which cause Vpr to oligomerize (Engler et al., 2001; 
Wecker et al., 2002). Across these studies the length of the alpha helices differed due to the 
proportion of TFE in the solvents used. 
Morellet et al. (2003) used CD3CN, a solvent with little hydrophobicity that approaches 
physiological conditions. This solvent allowed the following structural analysis: alpha 
helices 1, 2, and 3 (17-33, 38-50, 54-77), a flexible N-terminus (1-16) and a basic C-terminus 
(78-96). Each helix is amphipathic, containing hydrophobic and hydrophilic residues. The 
hydrophobic residues can allow for interactions with other proteins, most likely other 
cellular factors. In the third helix, L60, L67, I74, and I81 can form a leucine zipper (Morellet 
et al., 2003). The N-terminus consists largely of acidic residues, while the C-terminus 
consists largely of basic residues, arginine being the most prominent. The 3-D structure 
established by Morellet et al. (2003; 2009) shows a globular structure, in which hydrophobic 
interactions between the helices form a lipophilic core. Each of the helices in its amphipathic 
portions has acidic/basic residues, which are on the external face of the modeled protein. 
They possibly provide contacts for interactions with other proteins. The folding of the alpha 
helices entails that hydrophobic portions of the protein face outwards in contact with the 
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solvent. These unfavorable conditions could be ameliorated by binding to cellular partners. 
Mutational analyses of the protein have found many residues throughout the length of Vpr 
that maintain the structural integrity (Morellet et al., 2009). Single deletions of Y15 (see Table 
1 in the chapter by Figurski et al. for the amino acid codes), K27, and Q44 result in 
disruption of structure. The helical domains contain residues crucial to structure, especially 
those that form the hydrophobic core. The basic C-terminal residues also affect structure 
and stability of Vpr.  
6.1 Oligomerization 
The property of forming Vpr oligomers has recently come under scrutiny. Zhao et al. (1994) 
incorporated mutagenesis in their study to elucidate a rough map of residues in Vpr 
necessary for this function. Deletion of individual residues in the 36-76 region diminishes 
formation of oligomers. Mutagenesis of individual resides in the leucine-isoleucine motif 
(60LIRILQQLLFIHFR) in the third helix (amino acids 55-77) reduced the self-associative 
capacity of Vpr monomers. The residues at position 60, 61, 63, 64, 67, 68, 70, and 74 mutated 
from leucine or isoleucine to alanine or histidine disrupted binding between monomers 
(Zhao et al., 1994). The Q44 residue also plays an important role in Vpr oligomerization. 
Structural analysis of the second alpha helix (amino acids 38-50) reveals a hydrophilic 
glutamine at the 44th position (Morellet et al., 2009). Deletion of this residue by site-directed 
mutagenesis disrupted the secondary structure and abolished Vpr—Vpr interaction (Fritz et 
al., 2008). Fritz et al. (2008) revealed via 3-D modeling that the ΔQ44 mutation destabilizes 
the formation of the hydrophobic core and the self-interaction of the helices, thus providing 
an explanation for the inability of such mutants to oligomerize. Although Vpr 
oligomerization plays a role in other functions, this group did not find a relation between 
oligomerization and the ability of Vpr to induce apoptosis. 
Oligomerization seems necessary for other functions, such as nuclear localization and virion 
incorporation (Fritz et al., 2008; Fritz et al., 2010; Venkatachari et al., 2010). Venkatachari et 
al. (2010) hypothesized from a structural model of the oligomerization of Vpr that residues 
at the predicted helical interfaces contribute to dimerization. Substitution mutagenesis of 
A30 to leucine abolished dimerization. The authors attributed this to the position of A30 on 
the external face of the tertiary structure of Vpr, where it likely affects protein-binding. 
Furthermore, elimination of dimerization of Vpr abolished the ability of the protein to be 
incorporated into HIV virions. It also diminished its nuclear localization. These results 
implicate a necessary role of Vpr oligomerization in its incorporation into virions and, by 
extension, possibly playing a role in the infection of non-replicating immune cells, important 
targets of HIV-1. 
6.2 Nuclear import 
The nuclear import of the preintegration complex (PIC) upon entry of the virus enables 
productive infection to occur in targeted host cells, particularly non-dividing immune cells 
(e.g., macrophages/monocytes) (Bukrinsky et al., 1992). As Vpr is bound to the PIC, Vpr 
shuttles the viral contents into the nucleus, where integration occurs (Popov et al., 1998). An 
earlier study established the necessity of Vpr in productive viral replication in macrophages 
(Connor et al., 1995), eventually leading to the identification of importin-α as an essential 
host factor in this process (Nitahara-Kasahara et al., 2007). Sherman et al. (2001) mapped 
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non-canonical nuclear localization signals (NLS) throughout the helical domains and the C-
terminus of Vpr. This group used site-directed mutagenesis of its various domains in order 
to identify particular residues that function in nuclear import. In the C-terminus of Vpr, 
mutagenesis to change several arginine residues (those at positions 73, 76, 77, 85, 87, 88, and 
90) to alanine resulted in the distribution of Vpr throughout the cell or cytoplasm, 
suggesting the importance of this segment of Vpr. In the N-terminus, leucine motifs with the 
consensus sequence LXXLL in the first and third helices enable nuclear localization. The 
sequences for each motif are as follows: in the first helix, 22LLEEL26; and in the third helix, 
64LQQLL68. The following mutations disrupted nuclear localization most drastically: L22A, 
L23A, L26A, L64A, and L68A. Via site-directed mutagenesis, the authors established the 
importance of residues in both helices that are needed for Vpr translocation. 
7. G2 cell cycle arrest 
The G2 phase of the cellular life cycle serves as a checkpoint for the cell. Factors can halt the 
cell cycle progression into mitosis in the presence of excessive DNA damage. If these factors 
do not detect damage, the cell divides; but detection of chromatin disruption will activate 
factors, such as ATM (ataxia telangiectasia mutated) and ATR (ataxia telangiectasia mutated 
and Rad-3 related). These factors have downstream effects. Ultimately they hyper-
phosphorylate the Cdc2-Cyclin B1 complex, the major controller of cell progression into 
mitosis. Hyper-phosphorylation inactivates Cdc2-Cyclin B1 to prevent cell division. This 
process arrests the cell in the G2 phase (Morellet et al., 2009; Pandey et al., 2009; Sherman et 
al., 2002). Vpr expression in various cell types leads to G2 cell cycle arrest. It does so through 
increased expression of p21 through the p53 pathway, a major regulator of progression 
through the G2 and M phases (Chowdhury et al., 2003). Vpr seems to act synergistically 
with p53, perhaps inducing transcription of p21 through its own transactivation 
mechanisms. Although the purpose of the G2 arrest function of the virus is debatable, 
evidence suggests that it enhances transcription from the viral promoter, the long terminal 
repeat (LTR) of the HIV genome (Goh et al., 1998). One mechanism by which this occurs is 
through enhancing transactivation of the LTR in CD4+ T-cells via Vpr itself. Vpr binds to 
other host transcription factors, which bind to sites in the LTR, allowing viral transcription 
to occur. This effect is enhanced during G2 arrest (Gummuluru and Emerman, 1999).  
The C-terminal portion of the protein seems to be essential for induction of cell cycle arrest. 
Zhou and Ratner (2000) showed that the phosphorylated S79 residue is necessary for this 
function. Their mutagenesis study of substituting alanine for serine eliminated 
phosphorylation at this residue and abolished arrest in the G2 phase, correlating the two 
functions with each other. Furthermore, the mutation of G75A impaired G2 cell cycle arrest, 
as shown by Mahalingam et al. (1997). DeHart et al. (2007) proposed that Vpr hijacks the 
ubiquitin/proteasome pathway. One of the functions of this pathway is to target proteins 
for degradation and to cause G2 cell cycle arrest when needed. In their model, Vpr binds 
DCAF1, a subunit of the Cullin-4 E3 ubiquitin ligase, to lead to ubiquitination of an 
unknown host factor involved in halting the cell cycle progression. Change of Q65 to 
arginine eliminated this binding and impaired G2 cell cycle arrest. However, the group also 
generated an R80A substitution that also disrupted G2 cell cycle arrest; but this mutant Vpr 
maintained the ability to bind DCAF1. The authors interpreted these results to indicate that 
binding DCAF1 is necessary, but not sufficient, to cause G2 cell cycle arrest. A recent study 
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revealed a highly conserved motif in the C-terminus (79SRIG82), in which mutations that 
change each amino acid prohibit G2 cell cycle arrest. This study corroborates previous 
evidence of the functional role of the R80 residue (DeHart et al., 2007; Maudet et al., 2011). 
Mutagenesis studies using the substitutions R73A and R80A eliminated the induction of p21 
transcription, which is necessary for induction of G2 cell cycle arrest.  
While the C-terminal portion of Vpr seems necessary for G2 cell cycle arrest, several of the 
previously cited studies and others revealed that certain N-terminal residues may be 
indispensable for this function. At least two studies indicated that mutagenesis of A30 to 
leucine also abolished cell cycle arrest and reduced the transcription of p21 (Chowdhury et 
al., 2003; Mahalingam et al., 1997). As noted above, A30L eliminated oligomerization, which 
suggests a correlation between the functions of oligomerization and G2 cell cycle arrest. 
Also K27M (methionine for lysine 27) another substitution in the first helix, disables the 
induction of G2 cell cycle arrest. Overall the evidence indicates that N-terminal and C-
terminal moieties influence the conformational binding determinants of Vpr involved in G2 
cell cycle arrest. 
8. Apoptosis  
Apoptosis (programmed cell death) functions as a primary means of maintaining 
homeostasis among cells. Apoptosis can occur as a result of irreparable DNA damage or by 
disruption of essential cellular processes, such as transcription or translation. Infection by 
HIV disrupts the normal induction of apoptosis. Despite disrupting apoptosis, infected 
CD4+ T-cells still die (Groux et al., 1992; Jamieson et al., 1997). However, bystander cells not 
directly infected by HIV-1, such as CD8+ T-cells, neurons and other cell types, undergo 
apoptosis (Finkel et al., 1995; Zhang et al., 2003). The Vpr protein was shown to play a key 
role in the induction of apoptosis in several in vitro studies. Vpr was able to permeabilize the 
mitochondrial membrane and activate caspase 9 via cytochrome C release (Chen et al., 1999; 
Jacotot et al., 2000; Macreadie et al., 1995; Stewart et al., 1997). Jacotot et al. (2000) established 
the necessity of several arginine residues inside and between a repeated H(S/F)RIG motif in 
the Vpr amino acid sequence, specifically 71HFRIG75 and 78HSRIG82. Site-directed 
mutagenesis to generate the substitutions R73A, R77A, and R80A abolished the apoptotic 
effect of Vpr on Jurkat cells through the pathway involving the mitochondria. 
Correlation of the function of Vpr that influences apoptosis with the function that promotes 
G2 cell cycle arrest remains a complicated affair. Jacquot et al. (2007) reported experiments 
that indicated a correlation. The group generated several Vpr substitution mutants that 
abolished both cell cycle arrest and apoptosis. Their results were consistent with the model 
of G2 cell cycle arrest leading to the induction of apoptosis. Mutants K27M and A30L in the 
N-terminus of Vpr and R80A and R90K in the C-terminus disabled cytostatic capacity and 
reduced apoptosis in a T-cell line. However, Bolton and Lenardo (2007) reported that the 
Vpr with the R80A substitution attenuated apoptotic effects in Jurkat cells, although it 
remained G2 arrest-capable. Also Maudet et al. (2011) showed that the apoptotic function of 
alanine mutants in the 79SRIG82 motif, including R80, and the K27M substitution mutant 
remained intact without G2 cell cycle arrest. The evidence from such mutagenesis studies 
may indicate that, although G2 cell cycle arrest leads to apoptosis, a G2 cell cycle arrest-
independent apoptotic pathway exists. 
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Interestingly, Maudet et al. (2011) showed that the ability of Vpr to bind DCAF1 is not only 
necessary for induction of G2 cell cycle arrest, but for apoptosis as well. The substitution 
mutant Q65R eliminated DCAF1 binding, abolishing cell death. The S79A and K27M 
mutants retained their ability to cause apoptosis while losing G2 arrest function. 
Mutagenesis was done to produce the double mutants K27M/Q65R and S79A/Q65R. These 
mutants eliminated the G2 cell cycle arrest-independent induction of apoptosis. As DCAF1 
is essential for the targeting of proteins to the proteasome, the authors propose a model in 
which Vpr binds DCAF1 at a region containing the Q65 residue and functions as an adaptor 
to the ubiquitin/proteasome complex. Their mutagenesis studies suggest that Vpr contains 
two different binding domains that interact with two separate, and as yet unidentified, host 
targets. This ostensibly leads to ubiquitination and subsequent degradation of these 
proteins. Degradation of target 1 leads to G2 cell cycle arrest, and ubiquitination of target 2 
leads to apoptosis. However, these targets have yet to be identified. The model implies 
complex pathways. 
 
Fig. 2. Phylogeny of vpr Sequences Across Clades 
9. Vpr polymorphisms across subtypes 
A phylogenetic analysis of vpr sequences from clades A-D (including the highly prevalent 
subtype B shows a large diversity of sequences across the genetic lineages of HIV-1 subtypes 
(Figure 2). This indicates the existence of quasispecies of Vpr existing in the population and 
selective pressures acting on the vpr gene. Upon closer analyses of the sequences within the 
tree, several of the species between subtypes of Vpr show closer genetic relationships than 
other species within subtype. The variations in Vpr may correlate more to disease 
progression than to the clades. A comparative analysis of the frequencies of vpr alleles from 
long-term non-progressors (LTNP) and rapid progressors (RP) indicates the presence of 
mutations that are of interest (Table 1). 
 





of LTNP alignment 
Residue 
Residue conserved 




Consensus Seq PR 
alignment 
Residue conserved 
In the PR alignment 
(n=102) 
2 E 174 E 101 
3 Q 168 Q 96 
4 A 175 A 96 
5 P 176 P 101 
6 E 166 E 100 
7 D 170 D 91 
8 Q 175 Q 101 
9 G 165 G 102 
10 P 176 P 102 
11 Q 174 Q 98 
12 R 167 R 102 
13 E 168 E 100 
14 P 177 P 100 
15 Y 172 Y 96 
16 N 158 N 96 
17 E 169 E 96 
18 W 175 W 102 
19 T 153 T 93 
20 L 173 L 102 
21 E 174 E 102 
22 L 170 L 95 
23 L 170 L 102 
24 E 169 E 100 
25 E 172 E 102 
26 L 173 L 101 
27 K 172 K 102 
28 N 74 S 40 
29 E 171 E 101 
30 A 170 A 102 
31 V 171 V 101 
32 R 167 R 100 
33 H 174 H 101 
34 F 174 F 101 
35 P 175 P 101 
36 R 171 R 88 
37 I 50 V 51 
38 W 174 W 101 
39 L 175 L 99 
40 H 175 H 88 
41 S 89 G 71 
42 L 171 L 101 
43 G 171 G 101 
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of LTNP alignment 
Residue 
Residue conserved 




Consensus Seq PR 
alignment 
Residue conserved 
In the PR alignment 
(n=102) 
44 Q 175 Q 101 
45 H 118 H 72 
46 I 174 I 101 
47 Y 173 Y 101 
48 E 146 E 92 
49 T 174 T 98 
50 Y 175 Y 101 
51 G 169 G 101 
52 D 175 D 100 
53 T 175 T 100 
54 W 174 W 98 
55 A 123 A 58 
56 G 171 G 100 
57 V 174 V 100 
58 E 164 E 97 
59 A 166 A 96 
60 I 149 I 62 
61 I 167 I 96 
62 R 170 R 96 
63 I 136 I 53 
64 L 176 L 99 
65 Q 173 Q 97 
66 Q 174 Q 96 
67 L 174 L 98 
68 L 174 L 82 
69 F 176 F 100 
70 I 145 I 93 
71 H 173 H 100 
72 F 174 F 99 
73 R 174 R 100 
74 I 172 I 97 
75 G 158 G 95 
76 C 171 C 99 
77 R 106 R 52 
78 H 174 H 100 
79 S 175 S 98 
80 R 172 R 99 
81 I 171 I 97 
82 G 174 G 100 
83 I 171 I 99 
84 T 99 T 66 
 





of LTNP alignment 
Residue 
Residue conserved 




Consensus Seq PR 
alignment 
Residue conserved 
In the PR alignment 
(n=102) 
85 R 111 Q 40 
86 Q 143 Q 83 
87 R 168 R 94 
88 R 168 R 97 
89 A 140 A 83 
90 R 169 R 95 
91 N 170 N 56 
92 G 171 G 57 
93 A 153 A 55 
94 S 162 S 51 
95 R 173 R 58† 
Table 1†. Frequency Analysis of Amino Acids Resulting from vpr Alleles Found in the LTNP 
and RP Groups 
An approach using site-directed mutagenesis to study these substitutive polymorphisms 
will link these variants to possible effects on Vpr function and to the long-term non-
progressor and rapid progressor statuses.  
10. Mutagenesis studies in the context of disease progression and 
pathogenesis  
Wang et al. (1996) analyzed sequences of the vpr genes from an HIV-infected mother-child 
pair who showed no sign of AIDS from initial infection in 1983 to the time of the study in 
1995. These investigators found that samples from the mother and child had homogeneous 
and similar length polymorphisms in the C-terminal region of Vpr. However these 
polymorphisms were not present in samples from 30 patients who developed AIDS. Several 
other studies showed marked heterogeneity in vpr sequences derived from multiple patient 
samples (Ge et al., 1996; Kuiken et al., 1996). In addition to length polymorphisms, 
numerous studies have demonstrated an association between substitution mutants in the 
amino acid sequence of Vpr and disease (Caly et al., 2008; Lum et al., 2003; Tungaturthi et 
al., 2004). 
Caly et al. (2008) found a mutation, F72L, in several vpr sequences derived from a single 
patient with LTNP status. This mutation seems to be correlated with the disruption of 
nuclear import. However only a limited conclusion about prognosis can be drawn from this 
result because of the small sample size. Yedavalli and Ahmad (2001) reported several 
mutations from vpr sequences extracted from HIV-infected mothers with LTNP status who 
did not transmit the infection to the child during labor. They found polymorphisms from 
two separate patients that led to the A30S and G75R substitutions in Vpr. They also found 
                                                 
† Amino acid abbreviations follow standard conventions from the International Union of Pure and 
Applied Chemistry (IUPAC) (Nomenclature, 1968). 
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C-terminal deletions at an abundant frequency in another sample. This finding implies the 
possibility of structural changes to Vpr that might alter function in the context of disease 
progression. The involvement of Vpr at all stages of the HIV-1 life cycle suggests that this 
protein influences the development of disease and the severity of the outcome. Our 
hypothesis is that with a sufficient sample size, assessment of vpr sequences derived from 
the LTNP and RP groups will reveal signature polymorphisms that may be linked to 
progression of AIDS in vivo. This may occur through the disruption or enhancement of 
hallmark Vpr functions. Already several groups have suggested that unique, signature 
polymorphisms in Vpr culled from LTNP patient samples are associated with the reduction 
of host cell apoptosis (Lum et al., 2003; Somasundaran et al., 2002). 
However, given the complexities of the interrelated pathways by which Vpr induces 
apoptosis, as revealed by the mutagenesis studies detailed above, it is likely that the two 
published studies explain only a fraction of the causative factors behind the progression of 
HIV disease. Many questions need to be answered before the role of Vpr in disease 
induction is clear.  
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